Literature DB >> 15750613

Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.

L-J Chang1, X Liu, J He.   

Abstract

The high mutation rate of the human immunodeficiency virus (HIV) makes it difficult for any therapy employing a single anti-HIV targeting mechanism to sustain prolonged effect. In an attempt to explore novel therapy for AIDS, we developed and tested lentiviral small interfering RNA (siRNA) vectors targeting multiple highly conserved regions in the HIV type 1 (HIV-1) genome. The siRNA expression cassette was cloned into an extensively deleted HIV-1-derived lentiviral self-inactivating insulator (SIN) insulator [corrected] vector. Although some of the siRNAs targeting sites were also present in the helper construct of the vector system, the production of these lentiviral siRNA vectors were not significantly affected. When tested against different HIV-1 strains including pNL4-3 (subtype B), p89.6 (subtype B) and p90CF402.1.8 (subtype A/E recombinant), the siRNAs targeting conserved gag, pol, int and vpu, but not U3, nef or U5 regions, efficiently inhibited replication of all three viral strains. These lentiviral siRNA vectors also protected host cells from syncytium-forming macrophage- and T-cell-tropic HIV-1-induced cytotoxicity. Transduction of a long-term chronically infected human lymphoma cell line with lentiviral siRNAs resulted in stable inhibition of HIV-1 replication. Northern analysis showed that both genomic and subgenomic viral RNA species were downregulated. In addition, the viral RNA was inhibited in both the nuclear and cytoplasmic compartments of [corrected] chronically infected cells after prolonged passage, suggesting that [corrected] lentiviral siRNAs have a nuclear effect [corrected] Using these lentiviral siRNA [corrected] vectors, we further demonstrated reduced replication kinetics of HIV-1 in primary human peripheral blood lymphocytes. These results suggest that lentiviral siRNAs targeting multiple conserved HIV-1 sequences holds significant promise for the treatment of HIV-1 infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750613     DOI: 10.1038/sj.gt.3302509

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  40 in total

Review 1.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 2.  The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors.

Authors:  David W Emery
Journal:  Hum Gene Ther       Date:  2011-03-25       Impact factor: 5.695

3.  Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.

Authors:  Touraj Farazmandfar; Mohammad Reza Haghshenas; Majid Shahbazi
Journal:  Hum Gene Ther       Date:  2015-08-06       Impact factor: 5.695

4.  Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.

Authors:  Jian-Ping Zhang; Rui Zhang; Shih-Ting Tsao; Yu-Chen Liu; Xiaochuan Chen; Dao-Pei Lu; Paul Castillo; Lung-Ji Chang
Journal:  Blood Adv       Date:  2018-07-24

5.  Construction of a multiple targeting RNAi plasmid that inhibits target gene expression and FMDV replication in BHK-21 cells and suckling mice.

Authors:  Wei Cong; Shaoqiang Cui; Jiulian Chen; Xiaoping Zuo; Yonggan Lu; Weiyao Yan; Zhaoxin Zheng
Journal:  Vet Res Commun       Date:  2010-05-07       Impact factor: 2.459

Review 6.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

7.  Selection of potent non-toxic inhibitory sequences from a randomized HIV-1 specific lentiviral short hairpin RNA library.

Authors:  Carola Pongratz; Benjamin Yazdanpanah; Hamid Kashkar; Maik J Lehmann; Hans-Georg Kräusslich; Martin Krönke
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

Review 8.  Engineering RNA for targeted siRNA delivery and medical application.

Authors:  Peixuan Guo; Oana Coban; Nicholas M Snead; Joe Trebley; Steve Hoeprich; Songchuan Guo; Yi Shu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-15       Impact factor: 15.470

Review 9.  Genetic therapies against HIV.

Authors:  John J Rossi; Carl H June; Donald B Kohn
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

10.  A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs.

Authors:  Olivier ter Brake; Ben Berkhout
Journal:  J RNAi Gene Silencing       Date:  2005-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.